Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12389242 | 0.98 | ATM (0.45) | HPGDRAB9AMEN1KMT2AL3MBTL1 | |
| SCHEMBL18747345 | 0.94 | HPGD (0.41) | HPGDRAB9AMEN1KMT2AL3MBTL1 | |
| SCHEMBL23559482 | 0.83 | L3MBTL1 (0.44) | HPGDRAB9AMEN1KMT2AL3MBTL1 | |
| SCHEMBL13225632 | 0.82 | ALDH1A1 (0.46) | HPGDMEN1KMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL16591612 | 0.82 | L3MBTL1 (0.37) | HPGDRAB9AMEN1KMT2AL3MBTL1 | |
| SCHEMBL19532806 | 0.82 | L3MBTL1 (0.42) | HPGDRAB9AMEN1KMT2AL3MBTL1 | |
| SCHEMBL1725474 | 0.81 | L3MBTL1 (0.63) | HPGDRAB9AL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12139844 | 0.81 | TPSAB1 (0.47) | HPGDRAB9AMEN1KMT2AL3MBTL1 | |
| SCHEMBL25962133 | 0.81 | L3MBTL1 (0.36) | HPGDRAB9AMEN1KMT2AL3MBTL1 | |
| SCHEMBL20381555 | 0.79 | ALDH1A1 (0.55) | HPGDRAB9AMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746098-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746098-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20210188802-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-9566312-B2 | Cyclic peptides and use as medicines | NOVARTIS AG (CH) | 2017-02-14 | — | — | US | disclosed |
| US-20150306172-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | NOVARTIS AG (CH) | 2015-10-29 | — | — | US | disclosed |
| US-9072696-B2 | Cyclic peptides and use as medicines | NOVARTIS AG (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20140134132-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | NOVARTIS AG (CH) | 2014-05-15 | — | — | US | disclosed |
| US-20070191363-A1 | Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues | NEUROGEN CORPORATION (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191363-A1 | Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues | NEUROGEN CORPORATION (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746098-B2 | Proteasome activity enhancing compounds | PSMG3, PSMC1, PSMB11 | HPGD 3807/4885RAB9A 2592/4885MEN1 3370/4885 |
| US-20070191363-A1 | Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues | AHR, HCAR2, HCAR1 | HPGD 2129/4885RAB9A 1654/4885MEN1 4798/4885 |
| US-20210188802-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMC1, PSMB11 | HPGD 3807/4885RAB9A 2592/4885MEN1 3370/4885 |
| US-20140134132-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | PPIF, VIP, FKBP1B | HPGD 619/4885RAB9A 3061/4885MEN1 1814/4885 |
| US-20150306172-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | PPIF, VIP, MAVS | HPGD 595/4885RAB9A 2950/4885MEN1 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.